In this phase 1b study, using 75 mg/m2 azacitidine on days 1 to 7 of a 28-day cycle combined with a magrolimab priming dose of 1 mg/kg followed by a ramp up to 30 mg/kg weekly or fortnightly for patients with newly diagnosed TP53-mutated AML, the ORR was 48.6% in 72 patients with p53-mutated AML [23]. The gene discussed is TP53; the disease is acute myeloid leukemia.